Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk

Dow Jones

02/19

0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com)

(END) Dow Jones Newswires

February 18, 2026 20:58 ET (01:58 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612475661"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612475661\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612475661?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612475661","market":"nz","top_or_hot":-1,"title":"Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 20:58 ET (01:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Malaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMalaysian Healthcare May Benefit from Medical Tourism, Biopharma Push -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-19 09:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 20:58 ET (01:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612475661","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612475661","pubTimestamp":1771466280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","HCSG":"Healthcare Svcs Group Inc","LABU":"三倍做多标普生物-Direxion","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","BK4581":"高盛持仓","XLV":"健康照护类股ETF-SPDR","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4137":"综合支持服务"},"translate_title":"马来西亚医疗保健可能受益于医疗旅游和生物制药的推动——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1.5,"XBI":0.6,"LABU":0.6,"XLV":1.5},"content_text":"0158 GMT - The Malaysian healthcare sector may benefit from high-acuity medical tourism and more self-sufficient biopharmaceutical manufacturing and distribution this year, MBSB Research says in a note. The outlook is supported by an aging population, rising demand for precision treatments and government incentives for both public and private healthcare providers, it says. Ongoing digitalization and adoption of artificial intelligence in hospital administration and medical equipment should also enhance efficiency, it says. However, downside risks remain, including increases in medical costs, potential shifts in drug policies and pricing pressures stemming from global trade tariffs, it adds. MBSB maintains a positive rating on the Malaysian healthcare sector.(yingxian.wong@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 20:58 ET (01:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}